916,077 Shares in VYNE Therapeutics Inc. $VYNE Bought by Braidwell LP

Braidwell LP purchased a new stake in VYNE Therapeutics Inc. (NASDAQ:VYNE) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 916,077 shares of the company’s stock, valued at approximately $596,000. Braidwell LP owned approximately 1.37% of VYNE Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of VYNE. ADAR1 Capital Management LLC bought a new position in shares of VYNE Therapeutics in the 2nd quarter worth about $1,920,000. Nantahala Capital Management LLC bought a new stake in shares of VYNE Therapeutics during the 2nd quarter valued at about $1,301,400,000. Anson Funds Management LP acquired a new stake in VYNE Therapeutics during the fourth quarter worth about $739,000. T3 Companies LLC bought a new position in VYNE Therapeutics in the fourth quarter worth about $548,000. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in VYNE Therapeutics by 87.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock worth $1,063,000 after acquiring an additional 300,000 shares during the last quarter. Institutional investors and hedge funds own 83.78% of the company’s stock.

VYNE Therapeutics Stock Down 0.8%

Shares of VYNE stock opened at $28.32 on Thursday. The company has a market cap of $18.98 million, a P/E ratio of -74.54 and a beta of 2.00. The business has a 50 day moving average of $31.49 and a two-hundred day moving average of $31.48. VYNE Therapeutics Inc. has a 52 week low of $14.03 and a 52 week high of $79.75.

VYNE Therapeutics (NASDAQ:VYNE) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($3.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($3.33). The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.20 million. VYNE Therapeutics had a negative return on equity of 70.42% and a negative net margin of 4,726.21%.

VYNE Therapeutics Dividend Announcement

The company also recently declared a special dividend, which was paid on Thursday, July 23rd. Stockholders of record on Wednesday, July 22nd were issued a dividend of $19.00 per share.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.